Increased cardiovascular risk in T2DM demands early intervention; long-acting GLP-1 receptor agonists not only effectively lower glucose, but have multiple cardioprotective mechanisms of action and are associated with weight loss
GLP-1 Summit – Key learnings about the added benefits of GLP-1 in diabetes
Printable Q&A for Offline SubmissionQuiz-summary
0 of 15 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Information
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Results
Results
Time has elapsed
Categories
- Not categorized 0%
-
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Answered
- Review
- Question 1 of 15
1. Question
1. In the T2DM patient, there is accumulating evidence for established glucose-lowering agents such as the sulphonylureas and insulin having a cardioprotective role.
- Question 2 of 15
2. Question
2. Which statement is false?
- Question 3 of 15
3. Question
3. Which of the listed agents are not long-acting GLP-1 RAs?
- Question 4 of 15
4. Question
4. In the LEADER study, compared to placebo, liraglutide was associated with a reduction in cardiovascular mortality of:
- Question 5 of 15
5. Question
5. From the SUSTAIN-6 trial, compared to placebo, once weekly oral semaglutide reduced the risk of non-fatal stroke events by:
- Question 6 of 15
6. Question
6. CVOT meta-analysis shows all GLP-1 RAs meeting the MACE endpoints of cardiovascular death, fatal or non-fatal MI and fatal or non-fatal stroke.
- Question 7 of 15
7. Question
7. Real-world studies with liraglutide show a weight loss of:
- Question 8 of 15
8. Question
8. Of GLP-1 RA-naïve patients with baseline HbA1c >9% using oral semaglutide, what percentage attain HbA1c <7%?
- Question 9 of 15
9. Question
9. Compared to placebo, CVOT meta-analysis of the incidence of MI with GLP-1 RAs shows a:
- Question 10 of 15
10. Question
10. Which statement is true?
- Question 11 of 15
11. Question
11. Visceral adiposity is associated with risk for T2DM independently of BMI.
- Question 12 of 15
12. Question
12. Which statement is true? In T2DM, weight gain:
- Question 13 of 15
13. Question
13. GLP-1 RAs are associated with lowered body weight, reduced visceral adipose tissue and subcutaneous adipose tissue, as well as a smaller waist circumference.
- Question 14 of 15
14. Question
14. Which international authority recommends the first-line use of GLP-1 RAs or SGLT-2 inhibitors for T2DM patients with existing CVD, or at high/very high cardiovascular risk?
- Question 15 of 15
15. Question
15. Which GLP-1 RA does the ESC recommend for patients with T2DM and CVD, or at very high/high cardiovascular risk, to reduce the risk of death?
Do you like this? Share with a colleague
